Initially developed for atopic dermatitis, Enveda's lead asset ENV-294 is now showing promise in treating asthma.

Background: Observational studies have suggested the association between atopic dermatitis (AD) and the risks of autoimmune ... such as baricitinib (JAK1/2 inhibitor) and dupilumab (anti-IL-4Rα), ...

Johnson & Johnson has reached an agreement to acquire a bispecific antibody for atopic dermatitis (AD ... s blockbuster AD therapy Dupixent (dupilumab) – while blocking IL-31 may tackle other ...

Dupixent (dupilumab) was the first biologic medicine to get approval for atopic dermatitis in 2017, and since then has grown sales to more than $2 billion last year, with Sanofi suggesting it ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

Diagnosing atopic dermatitis is a matter of just ruling out all other causes of itching, which can be somewhat difficult at ...

Atopic dermatitis is a chronic inflammatory skin disease affecting a growing number of people worldwide. Marked by persistent ...

Atopic dermatitis (AD) is a chronically relapsing eczematous disease, more common in infants and children than in adults and very rare after midlife. The diagnosis of AD is not always easy in ...

Tapinarof, however, offers a potential solution by improving the skin barrier, reducing inflammation and relieving itch ...

Based on these findings, you diagnose his skin disease as atopic dermatitis (AD). AD is a common, genetic, recurring, inflammatory, pruritic skin disease, which usually develops during infancy or ...

Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on Astria Therapeutics (ATXS).Invest with Confidence: Follow ...

As temperatures drop, many people experience dry, red, and itchy skin, a condition that often worsens in winter.